AML Biomarker Gene Expression Analysis and Targeted Antibody Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating acute myeloid leukemia (AML), particularly those involving MLL-AF9 translocations, face challenges due to the complex genetic heterogeneity of the disease and the lack of specific biomarkers for precise diagnosis and targeted therapy.
Innovation Solution
The development of methods for diagnosing AML by measuring the expression of specific genes such as SYT17, FAM70A, NRG4, CLSTN2, SLC22A20, GIPR, KCNN2, TMEM105, CD276, IL31RA, TRPM4, RET, ITGA7, CD70, SERINC2, GPM6B, and SCUBE1, using techniques like PCR and RNA sequencing, and employing antibodies targeting these proteins for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for AML, then diagnosis can be performed, but precision and specificity are insufficient due to genetic heterogeneity
Solution Approach 1:
The patent segments the complex genetic landscape of AML by identifying and measuring expression levels of specific candidate genes (such as genes involved in MLL-AF9 translocation pathways) rather than attempting to analyze all genetic variations simultaneously. This segmentation approach transforms the intractable problem of genetic heterogeneity into manageable measurement of specific biomarker genes, thereby improving diagnostic precision without being overwhelmed by complexity.
Solution Approach 2:
The patent changes the measurement parameter from broad genetic analysis to specific gene expression levels. By focusing on quantifying mRNA or protein levels of candidate genes associated with AML subtypes, the method transforms the diagnostic approach into a precise measurement task that can distinguish between different AML types based on expression patterns rather than attempting to catalog all genetic variations.
2Object-affected harmful factors
If current treatment methods are used for AML, then treatment can be administered, but side effects are significant due to lack of targeted therapy
Solution Approach 1:
The patent applies local quality by identifying treatment targets that are specifically expressed in AML cells rather than universally expressed in all cells. By measuring candidate gene expression and targeting therapies to cells with high expression of these genes (such as MLL-AF9 fusion gene products), the treatment achieves local specificity to leukemia cells, minimizing damage to normal cells and reducing side effects while maintaining adaptability to different AML subtypes.
Solution Approach 2:
The patent introduces candidate gene expression levels as an intermediary between diagnosis and treatment selection. This intermediary measurement enables the matching of patients to appropriate targeted therapies based on their specific gene expression profiles, thereby enabling personalized treatment approaches that reduce side effects while maintaining versatility across different AML cases.
3Loss of information
If broad genetic analysis is performed, then comprehensive understanding is achieved, but diagnostic time and cost increase
Solution Approach 1:
The patent extracts only the most relevant genetic information needed for AML diagnosis by focusing on candidate genes with known or suspected roles in AML pathogenesis (such as MLL-AF9 translocation markers). This extraction approach removes unnecessary genetic analysis from the diagnostic workflow, retaining only the critical information needed for accurate diagnosis, thereby reducing diagnostic time and cost while maintaining comprehensive understanding of the clinically relevant genetic features.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable precise diagnosis of AML, assessment of minimal residual disease, and targeted therapy with reduced side effects by specifically identifying and targeting leukemia cells, improving treatment efficacy and patient outcomes.
Implementation Method 1
The method comprises obtaining cDNA corresponding to said one or more genes from said sample and measuring the level of said cDNA. In some embodiments, the method further comprises performing an amplification reaction on said cDNA. In certain embodiments, the amplification reaction comprises a polymerase chain reaction (PCR).
Implementation Method 2
In some embodiments, the level of said cDNA is measured by RNA sequencing (RNA-seq).
Implementation Method 3
In some embodiments, the method comprises contacting a protein encoded by said one or more of the genes with an antibody specifically recognizing said protein.
Data Source
AI summary
Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.